Literature DB >> 24155393

Kinase control of latent HIV-1 infection: PIM-1 kinase as a major contributor to HIV-1 reactivation.

Alexandra Duverger1, Frank Wolschendorf, Joshua C Anderson, Frederic Wagner, Alberto Bosque, Takao Shishido, Jennifer Jones, Vicente Planelles, Christopher Willey, Randall Q Cron, Olaf Kutsch.   

Abstract

Despite the clinical relevance of latent HIV-1 infection as a block to HIV-1 eradication, the molecular biology of HIV-1 latency remains incompletely understood. We recently demonstrated the presence of a gatekeeper kinase function that controls latent HIV-1 infection. Using kinase array analysis, we here expand on this finding and demonstrate that the kinase activity profile of latently HIV-1-infected T cells is altered relative to that of uninfected T cells. A ranking of altered kinases generated from these kinome profile data predicted PIM-1 kinase as a key switch involved in HIV-1 latency control. Using genetic and pharmacologic perturbation strategies, we demonstrate that PIM-1 activity is indeed required for HIV-1 reactivation in T cell lines and primary CD4 T cells. The presented results thus confirm that kinases are key contributors to HIV-1 latency control. In addition, through mutational studies we link the inhibitory effect of PIM-1 inhibitor IV (PIMi IV) on HIV-1 reactivation to an AP-1 motif in the CD28-responsive element of the HIV-1 long terminal repeat (LTR). The results expand our conceptual understanding of the dynamic interactions of the host cell and the latent HIV-1 integration event and position kinome profiling as a research tool to reveal novel molecular mechanisms that can eventually be targeted to therapeutically trigger HIV-1 reactivation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24155393      PMCID: PMC3911731          DOI: 10.1128/JVI.02682-13

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  56 in total

1.  Recruitment of TFIIH to the HIV LTR is a rate-limiting step in the emergence of HIV from latency.

Authors:  Young Kyeung Kim; Cyril F Bourgeois; Richard Pearson; Mudit Tyagi; Michelle J West; Julian Wong; Shwu-Yuan Wu; Cheng-Ming Chiang; Jonathan Karn
Journal:  EMBO J       Date:  2006-07-27       Impact factor: 11.598

2.  The receptor tyrosine kinase RON represses HIV-1 transcription by targeting RNA polymerase II processivity.

Authors:  Alicia Klatt; Zhiqiang Zhang; Parisa Kalantari; Pamela A Hankey; David S Gilmour; Andrew J Henderson
Journal:  J Immunol       Date:  2008-02-01       Impact factor: 5.422

3.  Inducible nuclear factor binding to the kappa B elements of the human immunodeficiency virus enhancer in T cells can be blocked by cyclosporin A in a signal-dependent manner.

Authors:  A Schmidt; L Hennighausen; U Siebenlist
Journal:  J Virol       Date:  1990-08       Impact factor: 5.103

4.  Host factor transcriptional regulation contributes to preferential expression of HIV type 1 in IL-4-producing CD4 T cells.

Authors:  Mingce Zhang; Adrian Clausell; Tanya Robinson; Jiyi Yin; Eric Chen; Leanne Johnson; Greta Weiss; Steffanie Sabbaj; Robert M Lowe; Fred H Wagner; Paul A Goepfert; Olaf Kutsch; Randy Q Cron
Journal:  J Immunol       Date:  2012-08-08       Impact factor: 5.422

5.  A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases.

Authors:  V M Richon; S Emiliani; E Verdin; Y Webb; R Breslow; R A Rifkind; P A Marks
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-17       Impact factor: 11.205

6.  ERK MAP kinase links cytokine signals to activation of latent HIV-1 infection by stimulating a cooperative interaction of AP-1 and NF-kappaB.

Authors:  X Yang; Y Chen; D Gabuzda
Journal:  J Biol Chem       Date:  1999-09-24       Impact factor: 5.157

7.  Selected drugs with reported secondary cell-differentiating capacity prime latent HIV-1 infection for reactivation.

Authors:  Takao Shishido; Frank Wolschendorf; Alexandra Duverger; Frederic Wagner; John Kappes; Jennifer Jones; Olaf Kutsch
Journal:  J Virol       Date:  2012-06-13       Impact factor: 5.103

8.  Inhibition of human immunodeficiency virus type-1 by cdk inhibitors.

Authors:  Irene Guendel; Emmanuel T Agbottah; Kylene Kehn-Hall; Fatah Kashanchi
Journal:  AIDS Res Ther       Date:  2010-03-24       Impact factor: 2.250

Review 9.  Reciprocal regulation of the nuclear factor of activated T cells and HIV-1.

Authors:  F Pessler; R Q Cron
Journal:  Genes Immun       Date:  2004-05       Impact factor: 2.676

10.  Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation.

Authors:  Hung-Chih Yang; Sifei Xing; Liang Shan; Karen O'Connell; Jason Dinoso; Anding Shen; Yan Zhou; Cynthia K Shrum; Yefei Han; Jun O Liu; Hao Zhang; Joseph B Margolick; Robert F Siliciano
Journal:  J Clin Invest       Date:  2009-10-01       Impact factor: 14.808

View more
  28 in total

1.  Stable Phenotypic Changes of the Host T Cells Are Essential to the Long-Term Stability of Latent HIV-1 Infection.

Authors:  Lillian Seu; Steffanie Sabbaj; Alexandra Duverger; Frederic Wagner; Joshua C Anderson; Elizabeth Davies; Frank Wolschendorf; Christopher D Willey; Michael S Saag; Paul Goepfert; Olaf Kutsch
Journal:  J Virol       Date:  2015-04-15       Impact factor: 5.103

2.  CD151 Expression Is Associated with a Hyperproliferative T Cell Phenotype.

Authors:  Lillian Seu; Christopher Tidwell; Laura Timares; Alexandra Duverger; Frederic H Wagner; Paul A Goepfert; Andrew O Westfall; Steffanie Sabbaj; Olaf Kutsch
Journal:  J Immunol       Date:  2017-09-27       Impact factor: 5.422

Review 3.  Understanding HIV latency: the road to an HIV cure.

Authors:  Matthew S Dahabieh; Emilie Battivelli; Eric Verdin
Journal:  Annu Rev Med       Date:  2015       Impact factor: 13.739

4.  Screening of an FDA-approved compound library identifies levosimendan as a novel anti-HIV-1 agent that inhibits viral transcription.

Authors:  Tsuyoshi Hayashi; Maxime Jean; Huachao Huang; Sydney Simpson; Netty G Santoso; Jian Zhu
Journal:  Antiviral Res       Date:  2017-08-24       Impact factor: 5.970

5.  KINOMIC ALTERATIONS IN ATYPICAL MENINGIOMA.

Authors:  Joshua C Anderson; Robert B Taylor; John B Fiveash; Rik de Wijn; G Yancey Gillespie; Christopher D Willey
Journal:  Med Res Arch       Date:  2015-07

6.  Curaxin CBL0137 has the potential to reverse HIV-1 latency.

Authors:  Maxime J Jean; Dawei Zhou; Guillaume Fiches; Weili Kong; Huachao Huang; Andrei Purmal; Katerina Gurova; Netty G Santoso; Jian Zhu
Journal:  J Med Virol       Date:  2019-05-01       Impact factor: 2.327

7.  The Cultured TCM Model of HIV Latency.

Authors:  Alberto Bosque
Journal:  Methods Mol Biol       Date:  2022

8.  Host T Cell Dedifferentiation Effects Drive HIV-1 Latency Stability.

Authors:  Alexander G Dalecki; Braxton D Greer; Alexandra Duverger; Elan L Strange; Eric Carlin; Frederic Wagner; Bi Shi; Kelsey E Lowman; Mildred Perez; Christopher Tidwell; Katarzyna Kaczmarek Michaels; Sophia Giattina; Stefan H Bossmann; Andrew J Henderson; Hui Hu; Olaf Kutsch
Journal:  J Virol       Date:  2022-01-12       Impact factor: 6.549

Review 9.  Strategies to target non-T-cell HIV reservoirs.

Authors:  Jonah B Sacha; Lishomwa C Ndhlovu
Journal:  Curr Opin HIV AIDS       Date:  2016-07       Impact factor: 4.283

10.  Desmin loss and mitochondrial damage precede left ventricular systolic failure in volume overload heart failure.

Authors:  Jason L Guichard; Michael Rogowski; Giulio Agnetti; Lianwu Fu; Pamela Powell; Chih-Chang Wei; James Collawn; Louis J Dell'Italia
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-04-28       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.